Daniel de Boer, ProQR CEO (via YouTube)
August 11, 2022 10:50 AM EDTUpdated 04:54 PM
R&D

Just months af­ter lay­offs and push­ing eye ther­a­py, Pro­QR to of­fload eye port­fo­lio in piv­ot to RNA-edit­ing

Paul Schloesser

Associate Editor

Near­ly four months af­ter join­ing dozens of oth­er biotechs in lay­ing off em­ploy­ees and trim­ming down its pipeline, Pro­QR is back at it again. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times